Global Primary Biliary Cirrhosis Drug Market Study 2016-2026, by Segment (Budesonide, FFP-104, … …), by Market (Clinic, Hospital, … …), by Company (AlbireoPharma, CymaBay Therapeutics, Inc., … …)
SKU ID :99ST-14632224 | Published Date: 28-Oct-2019 | No. of pages: 52Description
Summary
The global Primary Biliary Cirrhosis Drug market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Clinic
Hospital
Others
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
North America
Europe
Asia-Pacific
South America
Middle East & Africa
The global Primary Biliary Cirrhosis Drug market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Clinic
Hospital
Others
Company Coverage (Sales data, Main Products & Services etc.):
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
Major Region
MarketNorth America
Europe
Asia-Pacific
South America
Middle East & Africa
TOC
Tables & Figures
Companies
- PRICE
-
$1800$3600Buy Now